Mesoblast (MESO) Total Non-Current Liabilities (2015 - 2025)

Mesoblast's (MESO) quarterly Total Non-Current Liabilities came in at $79.6 million in Q4 2025, down 33.32% year-on-year from $119.3 million in Q4 2024, and down 5.98% quarter-over-quarter from $84.6 million in Q2 2025.

Mesoblast (MESO) Total Non-Current Liabilities (2015 - 2025) Analysis & Trends

Mesoblast has disclosed Total Non-Current Liabilities across 11 years of filings, most recently posting $79.6 million for Q4 2025.

  • Total Non-Current Liabilities for Q4 2025 came in at $79.6 million, down 33.32% year-over-year; the trailing twelve-month figure through Dec 2025 was $79.6 million (down 33.32% YoY), and the FY2025 annual result was $84.6 million, down 26.78% from the prior year.
  • Total Non-Current Liabilities came in at $79.6 million for Q4 2025 at Mesoblast, down from $84.6 million in the prior quarter.
  • In the past five years, Total Non-Current Liabilities ranged from a high of $130.2 million in Q4 2023 to a low of $66.6 million in Q1 2021.
  • The 5-year median for Total Non-Current Liabilities is $112.9 million (2022), against an average of $102.5 million.
  • Across the five-year window, Total Non-Current Liabilities sank 34.2% in 2021 and surged 68.61% in 2022, its largest moves.
  • Mesoblast's Total Non-Current Liabilities stood at $111.0 million in 2021, then advanced by 2.26% to $113.5 million in 2022, then increased by 14.72% to $130.2 million in 2023, then slipped by 8.36% to $119.3 million in 2024, then slumped by 33.32% to $79.6 million in 2025.
  • The last three Total Non-Current Liabilities figures came in at $79.6 million (Q4 2025), $84.6 million (Q2 2025), and $119.3 million (Q4 2024), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Total Non-Current Liabilities (Qtr)
1 Alterity Therapeutics 925,601.88 Bn 925,601.85 Bn - 42,980.09
2 Belite Bio 58,560.00 Bn 58,560.00 Bn - -
3 Quantum Biopharma 17,284.41 Bn 17,284.40 Bn - 11.03 Mn
4 Legend Biotech 2,809.00 Bn 2,808.71 Bn 242.10 Mn 95.20 Mn
5 Evaxion A 1,334.43 Bn 1,334.42 Bn - -
6 Akari Therapeutics 1,312.27 Bn 1,312.26 Bn - -
7 Psyence Biomedical 212.16 Bn 212.16 Bn - 644,700.00
8 Vertex Pharmaceuticals 114.83 Bn 107.58 Bn 2.59 Bn 5.87 Bn
9 Abivax 91.96 Bn 91.96 Bn - 64.76 Mn
10 Mesoblast 21.68 Bn 21.55 Bn - 79.55 Mn

Historic Data

Download Data
DateValue
Dec 31, 2025 79.55 Mn
Jun 30, 2025 84.62 Mn
Dec 31, 2024 119.31 Mn
Jun 30, 2024 115.56 Mn
Dec 31, 2023 130.19 Mn
Jun 30, 2023 125.60 Mn
Mar 31, 2023 114.36 Mn
Dec 31, 2022 113.48 Mn
Sep 30, 2022 112.89 Mn
Jun 30, 2022 113.73 Mn
Mar 31, 2022 112.38 Mn
Dec 31, 2021 110.98 Mn
Sep 30, 2021 69.17 Mn
Jun 30, 2021 69.05 Mn
Mar 31, 2021 66.65 Mn
Dec 31, 2020 77.54 Mn
Sep 30, 2020 86.37 Mn
Jun 30, 2020 94.13 Mn
Mar 31, 2020 101.29 Mn
Dec 31, 2019 112.48 Mn